Tonlamarsen for Severe High Blood Pressure After a Recent Hospital Stay
Tests tonlamarsen's blood pressure-lowering effect in adults recently hospitalized with severe high blood pressure.
Plain-language title generated from the registry record
Registry title: Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension
Key facts
- Where
- Arvada, Beavercreek, Chattanooga, Chicago, Cleveland, Detroit, Fort Mill, Homestead, Laredo, Paris, Port Orange, Staten Island, and Temple, United StatesSee the 13 sites
- Phase
- Phase 2
Where in United States
- Western Nephrology and Metabolic Bone Disease, PC - ArvadaArvada, United StatesTaking people
- Research Innovations, LLCBeavercreek, United StatesTaking people
- Chattanooga Research & Medicine CHARMChattanooga, United StatesTaking people
- Eagle Clinical ResearchChicago, United StatesTaking people
- Cleveland ClinicCleveland, United StatesTaking people
- Henry Ford HospitalDetroit, United StatesTaking people
- OnSite Clinical Solutions, LLCFort Mill, United StatesTaking people
- Homestead Associates in ResearchHomestead, United StatesTaking people
- Laguna Clinical Research AssociatesLaredo, United StatesTaking people
- Tapia Internal Medicine ClinicParis, United StatesTaking people
- Progressive Medical ResearchPort Orange, United StatesTaking people
- Richmond University Medical Center (RUMC)Staten Island, United StatesNo longer taking part
- Baylor Scott and White Research Institute - TempleTemple, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Kardigan, Inc.
- Trial code
- NCT07511361
- Record updated
- 15 October 2026
- Original description
The purpose of this study is to evaluate the blood pressure-lowering effect of tonlamarsen in adult participants who were recently hospitalized and concurrently experienced an episode of acute severe hypertension.Read full original descriptionShow less
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Two-Part Study to Evaluate the Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension
The purpose of this study is to evaluate the blood pressure-lowering effect of tonlamarsen in adult participants who were recently hospitalized and concurrently experienced an episode of acute severe hypertension.
Inclusion: Age 18 or older, body weight ≥ 50 kg with BMI ≤45.0 kg/m2; Ready for discharge or recently discharged from the hospital to home (within the past 7 days) during which evaluation and/or treatment of acute severe hypertension (documented SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg) occurred, as measured by a healthcare provider (HCP) within the 24 hours preceding hospitalization or during the initial 24 hours of hospitalization; At Screening and Randomization visit, average resting office systolic blood pressure ≥ 145 mmHg; Presence of established cardiovascular or renal disease.
Exclusion: Recent hospitalization for stroke, myocardial infarction or coronary revascularization within 30 days prior to screening; Has known history of secondary hypertension; Any malignancy requiring treatment within 5 years (except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated); History of and/or obvious clinical signs or symptoms of cirrhosis or other significant liver disease; Most recent hospitalization was for non-cardiovascular or non-renal conditions; Has abnormal thyroid function with clinical significance; Alanine aminotransferase or aspartate aminotransferase >2 x upper limit of normal.